Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + apatinib + nab-paclitaxel in second-line recurrent/metastatic cervical cancer
ChiCTR2100052395Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib and paclitaxel in cervical cancer (mCC), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoint: objective remission rate. Started Oct 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibpaclitaxel
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on ChiCTR2100052395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052395.